Sei Investments Co. Has $35.62 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Sei Investments Co. increased its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 22.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,182,751 shares of the company’s stock after acquiring an additional 217,487 shares during the quarter. Sei Investments Co.’s holdings in Teva Pharmaceutical Industries were worth $35,624,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 2.2% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company’s stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares during the period. WCM Investment Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after buying an additional 5,917,423 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of Teva Pharmaceutical Industries by 14.8% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after buying an additional 4,820,000 shares in the last quarter. Finally, Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $1,098,060,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.1%

TEVA opened at $30.78 on Monday. The stock has a market capitalization of $35.40 billion, a P/E ratio of 23.15, a P/E/G ratio of 3.25 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The firm’s fifty day simple moving average is $33.29 and its 200 day simple moving average is $32.69.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares of the company’s stock, valued at $2,825,792.40. This represents a 64.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president directly owned 63,647 shares of the company’s stock, valued at $2,247,375.57. This represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 465,931 shares of company stock worth $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. UBS Group boosted their target price on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Truist Financial increased their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Wall Street Zen lowered Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, Piper Sandler reiterated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.